Literature DB >> 33464307

Mapping and role of T cell response in SARS-CoV-2-infected mice.

Zhen Zhuang1, Xiaomin Lai1, Jing Sun1, Zhao Chen1, Zhaoyong Zhang1, Jun Dai2, Donglan Liu1, Yuming Li1, Fang Li1, Yanqun Wang1, Airu Zhu1, Junxiang Wang1, Wenhui Yang3, Jicheng Huang2, Xiaobo Li2, Lingfei Hu3, Liyan Wen1, Jianfen Zhuo1, Yanjun Zhang1, Dingbin Chen1, Suxiang Li1, Shuxiang Huang2, Yongxia Shi2, Kui Zheng2, Nanshan Zhong1, Jingxian Zhao1, Dongsheng Zhou3, Jincun Zhao1,4.   

Abstract

Virus-specific T cells play essential roles in protection against multiple virus infections, including SARS-CoV and MERS-CoV. While SARS-CoV-2-specific T cells have been identified in COVID-19 patients, their role in the protection of SARS-CoV-2-infected mice is not established. Here, using mice sensitized for infection with SARS-CoV-2 by transduction with an adenovirus expressing the human receptor (Ad5-hACE2), we identified SARS-CoV-2-specific T cell epitopes recognized by CD4+ and CD8+ T cells in BALB/c and C57BL/6 mice. Virus-specific T cells were polyfunctional and were able to lyse target cells in vivo. Further, type I interferon pathway was proved to be critical for generating optimal antiviral T cell responses after SARS-CoV-2 infection. T cell vaccination alone partially protected SARS-CoV-2-infected mice from severe disease. In addition, the results demonstrated cross-reactive T cell responses between SARS-CoV and SARS-CoV-2, but not MERS-CoV, in mice. Understanding the role of the T cell response will guide immunopathogenesis studies of COVID-19 and vaccine design and validation.
© 2021 Zhuang et al.

Entities:  

Year:  2021        PMID: 33464307     DOI: 10.1084/jem.20202187

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.

Authors:  Hye Won Jeong; Se-Mi Kim; Min Kyung Jung; Ji Yun Noh; Ji-Seung Yoo; Eun-Ha Kim; Young-Il Kim; Kwangmin Yu; Seung-Gyu Jang; Juryeon Gil; Mark Anthony Casel; Rollon Rare; Jeong Ho Choi; Hee-Sung Kim; Jun Hyoung Kim; Jihye Um; Chaeyoon Kim; Yeonjae Kim; Bum Sik Chin; Sungmin Jung; Jun Yong Choi; Kyoung-Ho Song; Yong-Dae Kim; Jun-Sun Park; Joon Young Song; Eui-Cheol Shin; Young Ki Choi
Journal:  Cell Rep Med       Date:  2022-09-19

2.  Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19.

Authors:  Athanasios Blanas; Haiko Karsjens; Aafke de Ligt; Elisabeth J M Huijbers; Karlijn van Loon; Stepan S Denisov; Canan Durukan; Diederik J M Engbersen; Jan Groen; Sven Hennig; Tilman M Hackeng; Judy R van Beijnum; Arjan W Griffioen
Journal:  iScience       Date:  2022-07-05

3.  Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.

Authors:  Hung-Chun Liao; Wan-Ling Wu; Chen-Yi Chiang; Min-Syuan Huang; Kuan-Yin Shen; Yu-Ling Huang; Suh-Chin Wu; Ching-Len Liao; Hsin-Wei Chen; Shih-Jen Liu
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

4.  Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.

Authors:  Murat Seyran
Journal:  Vaccine       Date:  2022-06-24       Impact factor: 4.169

5.  Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition.

Authors:  Hyukpyo Hong; Ji Yun Noh; Hyojung Lee; Sunhwa Choi; Boseung Choi; Jae Kyoung Kim; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2022-05-18       Impact factor: 5.851

6.  Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2.

Authors:  Benjamin Israelow; Tianyang Mao; Jonathan Klein; Eric Song; Bridget Menasche; Saad B Omer; Akiko Iwasaki
Journal:  Sci Immunol       Date:  2021-09-02

7.  Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies.

Authors:  Martin Qui; Nina Le Bert; Webber Pak Wo Chan; Malcolm Tan; Shou Kit Hang; Smrithi Hariharaputran; Jean Xiang Ying Sim; Jenny Guek Hong Low; Weiling Ng; Wei Yee Wan; Tiing Leong Ang; Antonio Bertoletti; Ennaliza Salazar
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

8.  DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model.

Authors:  Levi A Tamming; Diana Duque; Anh Tran; Wanyue Zhang; Annabelle Pfeifle; Emmanuel Laryea; Jianguo Wu; Sathya N Thulasi Raman; Caroline Gravel; Marsha S Russell; Anwar M Hashem; Reem M Alsulaiman; Rowa Y Alhabbab; Jun Gao; David Safronetz; Jingxin Cao; Lisheng Wang; Wangxue Chen; Michael J W Johnston; Simon Sauve; Michael Rosu-Myles; Xuguang Li
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

9.  Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.

Authors:  R Glenn King; Aaron Silva-Sanchez; Jessica N Peel; Davide Botta; Alexandria M Dickson; Amelia K Pinto; Selene Meza-Perez; S Rameeza Allie; Michael D Schultz; Mingyong Liu; John E Bradley; Shihong Qiu; Guang Yang; Fen Zhou; Esther Zumaquero; Thomas S Simpler; Betty Mousseau; John T Killian; Brittany Dean; Qiao Shang; Jennifer L Tipper; Christopher A Risley; Kevin S Harrod; Tsungwei Feng; Young Lee; Bethlehem Shiberu; Vyjayanthi Krishnan; Isabelle Peguillet; Jianfeng Zhang; Todd J Green; Troy D Randall; John J Suschak; Bertrand Georges; James D Brien; Frances E Lund; M Scot Roberts
Journal:  Vaccines (Basel)       Date:  2021-08-09

Review 10.  Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2.

Authors:  Reginald M Gorczynski; Robyn A Lindley; Edward J Steele; Nalin Chandra Wickramasinghe
Journal:  J Pers Med       Date:  2021-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.